Stockscreener 앱 받기
33.32
1.52%
0.50
시간 외 거래:
33.32
전일 마감가:
$32.82
열려 있는:
$32.95
하루 거래량:
838.05K
Relative Volume:
0.93
시가총액:
$1.54B
수익:
$203.27M
순이익/손실:
$-4.66M
주가수익비율:
-333.20
EPS:
-0.1
순현금흐름:
$3.47M
1주 성능:
+16.30%
1개월 성능:
+42.51%
6개월 성능:
+208.52%
1년 성능:
+127.13%
1일 변동 폭
$32.91
$33.92
1주일 범위
$27.50
$34.24
52주 변동 폭
$9.215
$34.24
Axogen Inc Stock (AXGN) Company Profile
명칭
Axogen Inc
전화
(386) 462-6817
주소
13631 PROGRESS BLVD., ALACHUA, FL
AXGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
33.32 | 1.52B | 203.27M | -4.66M | 3.47M | -0.10 |
|
ABT
Abbott Laboratories
|
125.08 | 218.05B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.52 | 144.86B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.02 | 139.34B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.36 | 130.75B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.19 | 49.78B | 5.88B | 1.34B | 799.60M | 2.3489 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Lake Street | Buy |
| 2024-07-01 | 개시 | Raymond James | Outperform |
| 2022-11-11 | 재개 | Jefferies | Buy |
| 2022-05-09 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | Guggenheim | Buy |
| 2020-06-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-05-07 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | 개시 | Canaccord Genuity | Buy |
| 2018-03-02 | 재확인 | Lake Street | Buy |
| 2018-01-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2017-11-30 | 개시 | Jefferies | Buy |
| 2017-11-21 | 재확인 | Lake Street | Buy |
| 2017-07-31 | 개시 | Leerink Partners | Outperform |
| 2017-06-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-06 | 개시 | ROTH Capital | Buy |
| 2016-11-22 | 업그레이드 | Lake Street | Hold → Buy |
| 2016-11-07 | 재확인 | Wedbush | Outperform |
| 2016-11-03 | 다운그레이드 | Lake Street | Buy → Hold |
| 2016-08-04 | 재확인 | Wedbush | Outperform |
| 2014-05-14 | 개시 | Dawson James | Buy |
| 2013-10-31 | 재확인 | Ladenburg Thalmann | Buy |
모두보기
Axogen Inc 주식(AXGN)의 최신 뉴스
Prudential Financial Inc. Trims Stake in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq
AxoGen Secures FDA Approval for Avance Nerve Scaffold - The Globe and Mail
HC Wainwright & Co. Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AxoGen Approves New CFO Compensation and Agreement - TipRanks
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Bu - GuruFocus
AXGN Sees Enhanced Price Target by HC Wainwright & Co. Analyst Y - GuruFocus
Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025 - simplywall.st
AxoGen (NASDAQ:AXGN) Shares Gap UpHere's What Happened - MarketBeat
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity - Investing.com Nigeria
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity By Investing.com - Investing.com South Africa
AxoGen, Inc. $AXGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
Will Axogen Inc. stock maintain growth storyWeekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Jefferies Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Bu - GuruFocus
AXGN: Lake Street Maintains "Buy" Rating and Raises Price Target to $40.00 | AXGN Stock News - GuruFocus
Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment - inkl
AxoGen stock price target raised to $36 from $27 at Raymond James - Investing.com Nigeria
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval By Investing.com - Investing.com Nigeria
AxoGen stock price target raised to $36 from $27 at Raymond James By Investing.com - Investing.com India
Axogen's Avance secures FDA approval for nerve repair - BioWorld MedTech
FDA approves Axogen's nerve repair graft - Reuters
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval - Investing.com
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval - Investing.com Nigeria
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval By Investing.com - Investing.com South Africa
Axogen, Inc. (AXGN) Stock: FDA Approval Boosts Avance as a Leading Nerve Repair Solution - parameter.io
Mizuho Begins Coverage on AxoGen (NASDAQ:AXGN) - MarketBeat
FDA Biologic Approval For AVANCE Might Change The Case For Investing In Axogen (AXGN) - simplywall.st
Axogen stock soars after FDA approval for nerve repair product By Investing.com - Investing.com South Africa
Axogen stock soars after FDA approval for nerve repair product - Investing.com
FDA Approves Axogen's (AXGN) Avance for Nerve Repair - GuruFocus
AXGN stock rises pre-market after FDA approves nerve repair graft - MSN
Why Is AXGN Stock Rising Today? - Stocktwits
Axogen (NASDAQ: AXGN) wins FDA Accelerated Approval for Avance nerve graft, eyes Q2 2026 launch - Stock Titan
Axogen, Inc. Announces FDA Approval of Avance® Biologics License - TradingView
Axogen Says FDA Approved Biologics License Application for Avance; Shares Rise Pre-Bell - marketscreener.com
Citizens reiterates Market Outperform rating on AxoGen stock, citing differentiated products - Investing.com
Will Axogen Inc. stock outperform Nasdaq indexDip Buying & Long-Term Capital Growth Strategies - Newser
Axogen gets FDA OK for Avance’s biologics license application (AXGN:NASDAQ) - Seeking Alpha
FDA approves Axogen’s nerve repair scaffold under biologics license By Investing.com - Investing.com South Africa
AxoGen Inc - Reuters
FDA approves Axogen’s nerve repair scaffold under biologics license - Investing.com India
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft-arwx) - The Manila Times
FDA Approves Axogen's AVANCE Nerve Allograft For Peripheral Nerve Repair - Nasdaq
Axogen, Inc. Receives FDA Approval for AVANCE® Biologics License Application to Treat Peripheral Nerve Discontinuities - Quiver Quantitative
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) - GlobeNewswire
FDA approves Axogen’s nerve repair graft - Northland News Radio
Fda: approval for avance was granted to axogen corporation - marketscreener.com
What momentum indicators show for Axogen Inc. stockEarnings Recap Report & Verified Chart Pattern Trade Signals - Newser
AxoGen, Inc. (NASDAQ:AXGN) Q3 2025 Earnings Call Transcript - MSN
FDA approves Axogen's nerve repair graft | Business Information & News | FE - Westlaw Today
Axogen Inc (AXGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.78%
0.34%
자본화:
|
볼륨(24시간):